WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Website Related Online Marketing Sunday, December 4, 2022 
Add Press Release News | News Feeds Feeds | Email This News Email


Severe Asthma Digital Marketing Trends Report 2022 Featuring Sanofi, Regeneron, Genentech, Novartis, GSK, AstraZeneca, Amgen, & Teva
Tuesday, November 29, 2022

DUBLIN, Nov. 21, 2022 /PRNewswire/ -- The "Digital Marketing Trends in Severe Asthma" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Sanofi/Regeneron's Dupixent.com achieved the highest traffic across branded severe asthma patient sites in the US from July 2021 to June 2022, with about 7,800,000 visits, followed by Novartis' Xolair.com, and GSK's Nucala.com.

The highest proportion of traffic to these sites originated from direct sources, followed by organic searches. Amgen/AstraZeneca's Tezspire.com had the highest amount of direct traffic (83%), while remaining brands, Dupixent, Cinqair, Nucala, and Xolair, had levels between 52-66%.

For patient branded sites, Sanofi/Regeneron spent the most on DDA for Dupixent.com at approximately $4.2 million, followed by GSK's Nucala.com at approximately $900,000. Dupixent.com was supported by the most paid keywords at approximately 10,650 keywords, followed by Tezspire.com at about 5,800 keywords.

For branded HCP sites in the US, Sanofi/Regeneron's Dupixenthcp.com had the highest number of visits at approximately 775,000 total visits, followed by AstraZeneca's Fasenrahcp.com, and GSK's Nucalahcp.com. The highest proportion of traffic to these sites originated from direct, followed by organic and referral sources.

Teva's Cinqairhcp.com had the highest proportion of traffic from direct searches (81%). Sanofi/Regeneron spent the most on DDA for Dupixenthcp.com at approximately $51,400, followed by Amgen/AstraZeneca's Tezspirehcp.com at approximately $17,100.

Between July 2021 and June 2022, the top 20 social media asthma posts by interaction from pharma were from Sanofi's Facebook accounts, Genentech's Instagram, Regeneron's Instagram, Fasenra's Facebook, and GSK's Instagram. AstraZeneca's Vik Asthma is the only severe asthma app detected from pharma in the US, with an estimated 30,700 downloads in 2021.

Most branded websites in EUCAN are patient-directed and few generated notable traffic between July 2021 and June 2022. Sanofi/Regeneron's Dupixentmyway.co.uk and Dupixent.co.uk achieved the highest traffic, with about 20,200 and 3,400 visits, respectively.

Between July 2021 and June 2022, eight of the top 20 social media asthma posts by interaction in EUCAN from pharma were from AstraZeneca Espana's Instagram account. No asthma mobile apps were detected from pharma in EUCAN.

Scope

    --  This report assesses key digital marketing metrics of pharma assets in
        severe asthma, including branded websites for patients and healthcare
        professionals (HCPs), mobile apps, and social media accounts.
    --  Metrics include website traffic volume, engagement, and source, digital
        display advertising (DDA), paid search engine optimization (SEO), mobile
        app downloads, and social media post interaction.
    --  Countries include the US, 4EU (Italy, France, Germany, and Spain), the
        UK, and Canada (EUCAN).

Reasons to Buy

    --  Understand the digital marketing competitive landscape in severe asthma,
        with a view of leading patient and HCP branded assets across different
        regions.
    --  See what tactics pharma companies are using to drive traffic to their
        severe asthma branded assets for patient and HCPs, such as DDA and paid
        SEO.
    --  Understand what sources of website traffic are generating the most
        visits to these assets, such as paid SEO, social media, or organic
        searches.
    --  Compare top branded assets for patients by how they address and support
        different patient needs.
    --  See what pharma social media accounts in severe asthma are the most
        active and achieving the most engagement.
    --  See leading mobile app offerings in severe asthma from pharma across
        different regions.

Key Topics Covered:

    --  Executive Summary
    --  US Patient Branded Websites
    --  US HCP Branded Websites
    --  US Digital Display Advertising and Search Engine Optimization
    --  US Mobile Apps and Social Media
    --  EUCAN Branded Websites
    --  EUCAN Mobile Apps and Social Media
    --  Appendix

Companies Mentioned

    --  Sanofi
    --  Regeneron
    --  Genentech
    --  Novartis
    --  GSK
    --  AstraZeneca
    --  Amgen
    --  Teva

For more information about this report visit https://www.researchandmarkets.com/r/dzcu6v

Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/severe-asthma-digital-marketing-trends-report-2022-featuring-sanofi-regeneron-genentech-novartis-gsk-astrazeneca-amgen--teva-301683667.html

SOURCE Research and Markets



Email This News Email | Submit To Slashdot Slashdot | Submit To Digg.com Digg | Submit To del.icio.us Del.icio.us | News Feeds Feeds

RELATED NEWS ARTICLES
Nav Etsy to Participate in Upcoming Investor Conferences | Dec 3, 2022
Nav AkkenCloud releases Hubspot integration for Staffing and Recruiting Agencies | Dec 3, 2022
Nav Greenspring Media Announces Winners of the Second Annual Midwest Home Design Awards | Dec 3, 2022
Nav Outlook on the Acute Migraine Drugs Global Market to 2028 - Introduction of Novel Therapies in the Treatment of Migraine Presents Opportunities | Dec 3, 2022
Nav Global Methanol Market to Reach $72.9 Billion by 2029 at a CAGR of 4.7% | Dec 3, 2022
Nav SuperCom Wins New Project in Northern California Valued at up to $4.25 million | Dec 3, 2022
Nav Thomson Reuters to Host Investor Webcast Today on Westlaw Precision | Dec 3, 2022
Nav Shop LC recognized as a finalist for BBB's 2022 Torch Awards for Ethics competition | Dec 3, 2022
Nav What Is Plastic Surgery SEO? | Dec 3, 2022
Nav Nation's Top Marketing Conference, Digital Summit, Return to Dallas with All-New Content, Trends and Tactical Guidance for Digital Marketers | Dec 3, 2022
NEWS SEARCH

FEATURED NEWS | POPULAR NEWS
Submit News | View More News View More News